---
schema_version: "secwatch.filing_event.v1"
accession: "0001549595-25-000094"
form_type: "8-K"
ticker: "NRIX"
cik: "0001549595"
company_name: "Nurix Therapeutics, Inc."
filed_at: "2025-07-09T23:59:59+00:00"
generated_at: "2026-05-18T08:53:07.644082+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Nurix Q2 FY2025 revenue $44.1M (+264% YoY); Sanofi extends STAT6 license; bexobrutideg 80.9% ORR in CLL

## Summary
- Revenue $44.1M (vs $12.1M YoY) driven by $30M Sanofi license extensions and $5M Gilead milestone.
- Net loss $43.5M ($0.52/sh) vs $44.5M ($0.71/sh) prior year; cash $485.8M.
- Sanofi extended STAT6 license for $15M payment; total $127M received; up to $465M in milestones remain.
- Bexobrutideg Phase 1 data: 80.9% ORR in r/r CLL including a complete response; favorable safety (no AFib, fungal infections).
- FDA cleared IND for IRAK4 degrader GS-6791/NX-0479; pivotal CLL trial for bexobrutideg expects to start H2 2025.

## SEC filing metadata
- accession: 0001549595-25-000094
- form_type: 8-K
- ticker: NRIX
- cik: 0001549595
- company_name: Nurix Therapeutics, Inc.
- filed_at: 2025-07-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549595/000154959525000094/0001549595-25-000094-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549595/000154959525000094/nrix-20250709.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001549595-25-000094
- JSON: https://secwatch.observer/filing/0001549595-25-000094.json
- Plain text: https://secwatch.observer/filing/0001549595-25-000094.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.